JP2015500334A - 後発性白内障抑制用組成物およびその製造方法 - Google Patents
後発性白内障抑制用組成物およびその製造方法 Download PDFInfo
- Publication number
- JP2015500334A JP2015500334A JP2014547077A JP2014547077A JP2015500334A JP 2015500334 A JP2015500334 A JP 2015500334A JP 2014547077 A JP2014547077 A JP 2014547077A JP 2014547077 A JP2014547077 A JP 2014547077A JP 2015500334 A JP2015500334 A JP 2015500334A
- Authority
- JP
- Japan
- Prior art keywords
- sulfasalazine
- composition
- cataract
- hyaluronic acid
- suppressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
1)細胞毒性:MTT assayを通して分析した。
2)蛋白質活性:Western blot分析法を利用して行った。
Claims (11)
- 親水性スルファサラジン;
1.4〜2.0%(w/v)のヒアルロン酸;および
水溶液を含む担体を含むことを特徴とする、後発性白内障抑制用組成物。 - 前記親水性スルファサラジンは、ペグ化(PEGylation)されたスルファサラジンを含むことを特徴とする、請求項1に記載の後発性白内障抑制用組成物。
- 前記親水性スルファサラジンの濃度が0.1〜1.5mMであることを特徴とする、請求項1に記載の後発性白内障抑制用組成物。
- 前記水溶液を含む担体は、蒸留水、リン酸緩衝液、均衡塩容液、および生理食塩水からなる群より選択された1種以上の薬剤学的に許容される担体を含むことを特徴とする、請求項1に記載の後発性白内障抑制用組成物。
- 塩酸、塩化ナトリウム、および塩化カリウムからなる群より選択された1つ以上の薬剤学的に許容される塩をさらに含むことを特徴とする、請求項1に記載の後発性白内障抑制用組成物。
- 請求項1〜5のいずれか1項に記載の後発性白内障抑制用組成物を含むことを特徴とする、眼球投与用製剤。
- スルファサラジンを親水化させる段階;
前記親水化されたスルファサラジンにヒアルロン酸粉を添加する段階;および
前記親水化されたスルファサラジンおよびヒアルロン酸粉を、33〜42℃で5〜24時間混合する段階を含むことを特徴とする、後発性白内障抑制用組成物の製造方法。 - 前記スルファサラジンを親水化させる段階は、スルファサラジンをペグ化(PEGylation)させる段階を含むことを特徴とする、請求項7に記載の後発性白内障抑制用組成物の製造方法。
- 前記スルファサラジンをペグ化(PEGylation)させる段階は、スルファサラジンをポリエチレングリコールを含む塩均衡溶液に添加する段階を含むことを特徴とする、請求項8に記載の後発性白内障抑制用組成物の製造方法。
- 前記スルファサラジンを親水化させる段階は、スルファサラジンの濃度を0.1〜1.5mMに調節する段階を含むことを特徴とする、請求項7に記載の後発性白内障抑制用組成物の製造方法。
- 前記親水化されたスルファサラジンにヒアルロン酸粉を添加する段階は、前記ヒアルロン酸の濃度が1.4〜2.0%(w/v)となるように調節する段階を含むことを特徴とする、請求項7に記載の後発性白内障抑制用組成物の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0133103 | 2011-12-12 | ||
KR1020110133103A KR101379930B1 (ko) | 2011-12-12 | 2011-12-12 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
PCT/KR2012/000205 WO2013089307A1 (ko) | 2011-12-12 | 2012-01-09 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015500334A true JP2015500334A (ja) | 2015-01-05 |
JP5843975B2 JP5843975B2 (ja) | 2016-01-13 |
Family
ID=48612735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014547077A Expired - Fee Related JP5843975B2 (ja) | 2011-12-12 | 2012-01-09 | 後発性白内障抑制用組成物およびその製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9364552B2 (ja) |
EP (1) | EP2792356A4 (ja) |
JP (1) | JP5843975B2 (ja) |
KR (1) | KR101379930B1 (ja) |
CN (1) | CN104168901A (ja) |
BR (1) | BR112014014038A2 (ja) |
CA (1) | CA2858699A1 (ja) |
IN (1) | IN2014DN05738A (ja) |
WO (1) | WO2013089307A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017119462A1 (ja) * | 2016-01-06 | 2017-07-13 | 学校法人慶應義塾 | 抗腫瘍剤 |
JP2018538315A (ja) * | 2015-12-18 | 2018-12-27 | ビーエムアイ コリア カンパニー リミテッド | 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法 |
JP2019535708A (ja) * | 2016-11-10 | 2019-12-12 | メディスカ ファーマシューティック インコーポレイテッド | 薬剤の配合方法およびシステム |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101379930B1 (ko) | 2011-12-12 | 2014-04-14 | 가톨릭대학교 산학협력단 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
KR101412776B1 (ko) * | 2013-03-11 | 2014-07-01 | 가톨릭대학교 산학협력단 | 각결막염 치료용 점안제 조성물 및 이의 제조 방법 |
US10385096B2 (en) * | 2016-08-30 | 2019-08-20 | Council Of Scientific & Industrial Research | Pro-Amb reverse turn restricted bioactive peptide analogues |
US11026460B2 (en) * | 2017-03-03 | 2021-06-08 | Stormy McCowen TAYLOR | Hair filler device |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008505179A (ja) * | 2004-06-30 | 2008-02-21 | アドバンスト メディカル オプティクス, インコーポレーテッド | 水晶体再生の増進におけるヒアルロン酸 |
KR20080092631A (ko) * | 2007-04-13 | 2008-10-16 | 가톨릭대학교 산학협력단 | 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093487A (en) * | 1986-01-06 | 1992-03-03 | Mobay Corporation | Low viscosity high molecular weight filter sterilizable hyaluronic acid |
KR100490286B1 (ko) | 2001-09-12 | 2005-05-17 | 주식회사 뉴로테크 | 설파살라진을 활성성분으로 함유하는 것을 특징으로 하는망막손상 치료용 안약 조성물과 그 제조방법 |
AU2003255892B2 (en) | 2002-08-07 | 2008-02-21 | Laboratoire Medidom S.A. | Process for preparing a sterile high molecular weight hyaluronic acid formulation |
KR20030069917A (ko) | 2003-06-27 | 2003-08-27 | 주식회사 뉴로테크 | 안질환 예방 및 치료용 약학적 조성물 |
CN102106838A (zh) | 2009-12-23 | 2011-06-29 | 上海信谊嘉华药业有限公司 | 一种柳氮磺吡啶肠溶制剂及其制备方法 |
CN102225220A (zh) | 2011-06-14 | 2011-10-26 | 天津晶明新技术开发有限公司 | 眼科手术粘弹剂 |
KR101379930B1 (ko) | 2011-12-12 | 2014-04-14 | 가톨릭대학교 산학협력단 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
-
2011
- 2011-12-12 KR KR1020110133103A patent/KR101379930B1/ko active IP Right Grant
-
2012
- 2012-01-09 CN CN201280069538.7A patent/CN104168901A/zh active Pending
- 2012-01-09 CA CA2858699A patent/CA2858699A1/en not_active Abandoned
- 2012-01-09 JP JP2014547077A patent/JP5843975B2/ja not_active Expired - Fee Related
- 2012-01-09 US US14/364,325 patent/US9364552B2/en not_active Expired - Fee Related
- 2012-01-09 IN IN5738DEN2014 patent/IN2014DN05738A/en unknown
- 2012-01-09 EP EP12858133.7A patent/EP2792356A4/en not_active Withdrawn
- 2012-01-09 WO PCT/KR2012/000205 patent/WO2013089307A1/ko active Application Filing
- 2012-01-09 BR BR112014014038A patent/BR112014014038A2/pt not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008505179A (ja) * | 2004-06-30 | 2008-02-21 | アドバンスト メディカル オプティクス, インコーポレーテッド | 水晶体再生の増進におけるヒアルロン酸 |
KR20080092631A (ko) * | 2007-04-13 | 2008-10-16 | 가톨릭대학교 산학협력단 | 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물 |
Non-Patent Citations (1)
Title |
---|
JPN6015016648; 日本眼科学会雑誌, 2010, Vol.114, p.303 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018538315A (ja) * | 2015-12-18 | 2018-12-27 | ビーエムアイ コリア カンパニー リミテッド | 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法 |
WO2017119462A1 (ja) * | 2016-01-06 | 2017-07-13 | 学校法人慶應義塾 | 抗腫瘍剤 |
US11376266B2 (en) | 2016-01-06 | 2022-07-05 | Keio University | Antitumor agent |
JP2019535708A (ja) * | 2016-11-10 | 2019-12-12 | メディスカ ファーマシューティック インコーポレイテッド | 薬剤の配合方法およびシステム |
US11883359B2 (en) | 2016-11-10 | 2024-01-30 | Medisca Pharmaceutique Inc. | Adapter for use in a planetary mixer |
Also Published As
Publication number | Publication date |
---|---|
JP5843975B2 (ja) | 2016-01-13 |
US20140378410A1 (en) | 2014-12-25 |
KR20130066319A (ko) | 2013-06-20 |
BR112014014038A2 (pt) | 2017-06-13 |
CN104168901A (zh) | 2014-11-26 |
KR101379930B1 (ko) | 2014-04-14 |
CA2858699A1 (en) | 2013-06-20 |
US9364552B2 (en) | 2016-06-14 |
EP2792356A1 (en) | 2014-10-22 |
IN2014DN05738A (ja) | 2015-04-10 |
EP2792356A4 (en) | 2015-11-11 |
WO2013089307A1 (ko) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5843975B2 (ja) | 後発性白内障抑制用組成物およびその製造方法 | |
Alió et al. | Artisan phakic iris claw intraocular lens for high primary and secondary hyperopia | |
TW201105363A (en) | Eye drop for macular edema treatment | |
WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
JP6820658B2 (ja) | ジピリダモールを用いる眼疾患の治療において使用するための組成物 | |
US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
KR101840256B1 (ko) | 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법 | |
KR100894042B1 (ko) | 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물 | |
TW201815397A (zh) | 眼科用劑、眼科用藥、以及(a)羥丙基甲基纖維素及(b)維生素e類的用途 | |
KR101723703B1 (ko) | 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물 | |
JP2023075278A (ja) | 薬剤送達用生体溶解性医薬ゲル | |
US9254289B2 (en) | Methods for treating eye disorders using dipyridamole | |
JP2021511323A (ja) | 多標的阻害剤の懸濁組成物 | |
CN112426414B (zh) | 一种眼部抗黏连和防蓝光损伤的护理液及其制备方法 | |
JP2011256163A (ja) | 眼科用剤 | |
US20230201030A1 (en) | Dissolvable medical device for drugs delivery | |
JP3504656B2 (ja) | 水性医薬組成物 | |
CN115645420A (zh) | 甘露糖及其药用衍生物在制备预防和/或治疗年龄相关性黄斑变性的药物中的应用 | |
CN103405766B (zh) | 一种贝伐单抗滴眼液及其制备方法 | |
Morgenstern | TREAT CORNEAL ECTASIA WITH CROSSLINKING. | |
CN111643448A (zh) | 一种盐酸莫西沙星眼用凝胶剂及其制备方法 | |
CN110200904A (zh) | 一种降眼压缓释滴眼组合物及其制备方法 | |
TW200906386A (en) | Compositions with anti-angiogenic activity | |
TW201417818A (zh) | 曲安奈德眼用製劑及其製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150724 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151027 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151117 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5843975 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |